Max Mamonkin

IL15 increases the expansion of CAR T cells and induces antitumor responses in patients with GPC3+ solid tumors (i.e. liver cancer). nature.com/articles/s4158…

A cell intrinsic NKG2A/C switch receptor to overcome the critical HLA-E checkpoint. Fun collaboration with the Michel Sadelain lab. Michelle Sætersmoen, Ivan Kotchetkov, @LambertoTR @CoE_PRIMA @UniOslo_MED @Oslounivsykehus @CIM_Sweden

I am very pleased to announce the work I did as a graduate student in the labs of Crystal Mackall and Everett Meyer has been published in Nature Communications, open access! nature.com/articles/s4146…

Columbia welcomes CAR-T pioneer Michel Sadelain, MD, PhD, as the inaugural director of the new Columbia Initiative for Cell Engineering and Therapy and director of the Cancer Cell Therapy Initiative at the Herbert Irving Comprehensive Cancer Center. ➡️columbiamed.link/3zCR9iI

Recruiting faculty to the Dept of Molecular and Cellular Biology at Baylor College of Medicine in Houston, TX! Recruiting broadly in cancer and cell biology. Submit by October 1, 2024, for full review. #cellbio @BCMhouston bcm.edu/departments/mo… jobs.sciencecareers.org/job/659987/ten…

@dlwagner13 Very cool!

Preprint alert 🚨 Up to 90% CAR knock-in rates in primary human T cells - without drug enhancers? 🧐 Single-stranded HDR templates with truncated Cas12a binding sequences improve knock-in efficiencies in primary human T cells biorxiv.org/content/10.110… 🧵👇

My department (MIT Biological Engineering) is hiring at the Assistant Professor level! We are looking for someone in immunology/immunotherapy/immune engineering, broadly defined. be.mit.edu/about/open-fac…

@may_daher @ScienceTM Well done, May & team

Excited to share our manuscript published in @ScienceTM, where we describe a novel NK immune evasion strategy in AML. We found that #BATF is a key transcription factor driving epigenetic reprogramming in NK cells in AML. This TF is induced by the canonical TGF-β/SMAD pathway and leads to persistent NK cell dysfunction. This dysfunction can be prevented by deleting BATF or TGFBR2 upstream, but once established, it cannot be reversed. Designed to overcome epigenetic scarring, we look forward to bringing this novel CAR-NK cell approach to the clinic to improve outcomes for AML patients. @mdandersonnews @lab_rezvani @bijender2050 #AML #NK #CRISPR #epigenetics #BATF

Great step forward in humanized mouse models. Using iPSC-derived CD34+ iHSC which engraft and produce human multi-lineage progeny in immunodeficient NBSGW mice nature.com/articles/s4158…

An interesting POC of T cell therapy in CNS injury models: autoreactive MOG-specific T cells infiltrate the lesion and suppress tissue damage, counter-intuitively in part via IFNg secretion. But you have to act fast. nature.com/articles/s4158…

Excellent results with autologous CD7-PEBL CART in T-ALL from Singapore and Rome nature.com/articles/s4159…

@jaehyukchoimd Yeah CD5 is known to internalize quickly upon binding to an antibody, which was used in the 90s with ADC. But CD5 internalization speed/extent depends on the targeted epitope and may not work with all CARs. Also CD7 and other Ag don't behave the same way

@MaxMamonkin cool study. have to read it. is this mechanism conserved in other disease or physiological contexts?

T cells express a ton of CD5, so why CD5 CAR T cells don't kill each other? Turns out, they completely degrade CD5 protein and thus evade fratricide. Unique mechanism unveiled in a mechanistic study - and PhD thesis work - by Royce Ma: cell.com/cell-reports-m…

The genomic basis of childhood T-lineage acute lymphoblastic leukaemia | Nature nature.com/articles/s4158…

Congrats to the now Dr. @_ruchipatel for the publication of her PhD thesis in @SciImmunology. We show here that CD5 deletion enhances CART immunotherapy in multiple solid and liquid cancer models. @PennMedicine @RuellaLab science.org/doi/10.1126/sc…

Are all hybrid antigen receptors as easy to design as CARs? Definitely not! doi.org/10.1158/2159-8… (1/4)

Comprehensive thread highlighting our most recent work now out in @CellStemCell describing a novel approach to increase persistence of allogeneic cell therapy products. Work led by amazing @QuirinHammer and @KarloPerica. @CoE_PRIMA, @Oslounivsykehus @UniOslo_MED @karolinskainst

Limiting institutional overhead on NIH grants?

@DrPHanley Awesome news, Pat. Congratulations to you both!

Some personal news to share this week: